Jeffrey Lieberman

From Wikipedia, the free encyclopedia
Jeffrey A. Lieberman
Shoulder high portrait of sixty year old man in a white lab coat
Born1948
CitizenshipAmerican
Alma materMiami University (B.S.)
George Washington University Medical School (M.D.)
Saint Vincent's Catholic Medical Center
Known forSchizophrenia research, NIMH CATIE study[1]
Children2
Awards for Schizophrenia Research from the National Association for Research in Schizophrenia and Affective Disorders; the Adolph Meyer Award from the American Psychiatric Association; the Research Award from the National Alliance on Mental Illness, and the Neuroscience Award from the International College of Neuropsychopharmacology
Scientific career
FieldsPsychiatry
InstitutionsAmerican Psychiatric Association, Columbia University Vagelos College of Physicians and Surgeons, New York State Psychiatric Institute, University of North Carolina School of Medicine, Mount Sinai School of Medicine, Albert Einstein College of Medicine, Zucker Hillside Hospital of Long Island Jewish Medical Center

Jeffrey Alan Lieberman (born 1948) is an American psychiatrist who specializes in schizophrenia and related psychoses and their associated neuroscience (biology) and pharmacological treatment (psychiatric drugs). He was principal investigator for CATIE, the largest and longest independent study ever funded by the United States National Institute of Mental Health to examine existing therapies for schizophrenia.[2] He was president of the American Psychiatric Association from May 2013 to May 2014.[3]

Lieberman is the Lawrence E. Kolb Professor and Chairman of Psychiatry at the Columbia University Vagelos College of Physicians and Surgeons and director of the New York State Psychiatric Institute. He also holds the Lieber Chair and directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia and serves as the psychiatrist-in-chief of NewYork-Presbyterian Hospital/Columbia University Irving Medical Center.[4]

Education[]

Lieberman graduated from Miami University in 1970, and then received his medical degree from the George Washington School of Medicine in 1975. He completed his postgraduate training in psychiatry at St. Vincent's Hospital and Medical Center of New York Medical College.

Career[]

Lieberman he was on the faculties of the Mount Sinai School of Medicine and Albert Einstein College of Medicine, and served as director of research at the Zucker Hillside Hospital of Long Island Jewish Medical Center.[4] He served as vice-chairman for Research and Scientific Affairs in the UNC Department of Psychiatry and Director of the Mental Health and Neuroscience Clinical Research Center at the University of North Carolina at Chapel Hill School of Medicine.[4]

Lieberman is the Lawrence E. Kolb Professor and Chairman of Psychiatry at the Columbia University Vagelos College of Physicians and Surgeons and director of the New York State Psychiatric Institute. He also holds the Lieber Chair and directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia and serves as the psychiatrist-in-chief of NewYork-Presbyterian Hospital/Columbia University Irving Medical Center.[4]

Lieberman is or has been a member of the advisory committee for Neuropharmacologic and Psychopharmacologic Drugs of the Food and Drug Administration, the Planning Board for the Surgeon General's Report on Mental Health, the Committee on Research on Psychiatric Treatments of the APA, the APA Work Group for the Development of Schizophrenia Treatment Guidelines, the Brain Disorders and Clinical Neuroscience Review Committee, the National Advisory Mental Health Council of the NIMH, and currently[when?] chairs the APA Council of Research.[citation needed]

Research[]

Lieberman's research has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. In this context, his work has advanced our understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs.[4]

His research has been supported by grants from the National Institutes of Health and the NARSAD, Stanley, and Mental Illness Foundations.[4]

CATIE study[]

Notably, Lieberman served as principal investigator for Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) sponsored by the National Institute of Mental Health (NIMH).[1] The investigators compared a, "first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study".[5] "Probably the biggest surprise of all was that the older medication produced about as good an effect as the newer medications, three of them anyway, and did not produce neurological side effects at greater rates than any of the other drugs," Lieberman told The New York Times.[6]

Journals edited[]

Lieberman serves, or has served, as associate editor of the American Journal of Psychiatry, Biological Psychiatry, Neuropsychopharmacology, Acta Psychiatrica Scandinavica, Schizophrenia Research, NeuroImage, The International Journal of Neuropsychopharmacology, and Schizophrenia Bulletin.[citation needed]

Publications[]

Lieberman's work has been reported in more than 700 articles in the scientific literature and he has edited or co-edited 17 books, including the textbook Psychiatry (currently in its second edition), Textbook of Schizophrenia, Comprehensive Care of Schizophrenia, Psychiatric Drugs and Ethics in Psychiatric Research: A Resource Manual on Human Subjects Protection.[4]

In 2015, he published the book Shrinks: the Untold Story of Psychiatry (Little Brown). A four-part series, tentatively titled "In Search of Madness: The Untold Story of Mental Illness," based on his book, Shrinks, is scheduled for prime-time national broadcast on PBS in April 2022.

His new book on schizophrenia will be published by Scribner in 2022.

Awards and honors[]

Lieberman is a member of the National Academy of Sciences Institute of Medicine and a fellow of the American Association for the Advancement of Science (AAAS). He received the for Schizophrenia Research from NARSAD,[7] the Adolph Meyer Award from the American Psychiatric Association (APA), the Stanley R. Dean Award for Schizophrenia Research from the American College of Psychiatrists, the APA Research Award, the APA Kempf Award for Research in Psychobiology, the APA Gralnick Award for Schizophrenia Research, the Ziskind-Somerfeld Award of the Society of Biological Psychiatry, the Ernest Strecker Award of the University of Pennsylvania, the Lilly Neuroscience Award from the Collegium Internationale Neuro-Psychopharmacologicum for Clinical Research, the Scientific Research Award[8] and the Exemplary Psychiatrist Award from the National Alliance on Mental Illness, the Ed Hornick Memorial Award of The New York Academy of Medicine,[9] the Strecker Award of the Department of Psychiatry at the University of Pennsylvania.[10]

Invocation of Goldwater rule during Donald Trump's presidency[]

During Donald Trump's presidency, Lieberman used the association's Goldwater rule to become a vocal critic of prominent psychiatrist colleagues such as Robert Jay Lifton, Judith Lewis Herman, and Bandy X. Lee.[11][12] Lee responded that this amounted to "vigorously silencing the warnings of mental health professionals and boosting the president’s ability to remain without accountability."[13]

Reception[]

A review of Lieberman's 2015 book Shrinks in The Guardian criticized the book for focusing almost entirely on American psychiatry, for its "triumphalist" narrative, and for failing to discuss Lieberman's financial relationship with pharmaceutical companies.[14]

Personal life[]

Lieberman resides in New York City[4] with his wife, Rosemarie,[15] and two sons.[16]

Notes[]

  1. ^ Jump up to: a b "Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)". National Institute of Mental Health. 2005 to 2008. Archived from the original on May 26, 2013. Retrieved May 26, 2013. Check date values in: |date= (help)
  2. ^ "Questions and Answers About the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness Study (CATIE) — Phase 1 Results". National Institute of Mental Health, U.S. Department of Health and Human Services. September 2005. Archived from the original on May 26, 2013. Retrieved May 28, 2013.
  3. ^ "Jeffrey A. Lieberman". Columbia University. Retrieved May 26, 2013.
  4. ^ Jump up to: a b c d e f g h "Jeffrey Lieberman, M.D." Columbia University Department of Psychiatry. 2005 to 2008. Retrieved May 26, 2013. Check date values in: |date= (help)
  5. ^ Lieberman, Jeffrey A.; et al. (September 22, 2005). "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia". The New England Journal of Medicine. Massachusetts Medical Society. 353 (12): 1209–1223. doi:10.1056/NEJMoa051688. PMID 16172203.
  6. ^ Carey, Benedict (September 20, 2005). "Little Difference Found in Schizophrenia Drugs". The New York Times. Retrieved May 30, 2013.
  7. ^ "Prestigious Lieber Prize for Research Awarded to Jeffrey A. Lieberman, M.D". National Institute of Mental Health. October 12, 2006. Archived from the original on April 27, 2013. Retrieved May 26, 2013.
  8. ^ "Reception and Presentation of the 2011 NAMI Scientific Research Award". National Alliance on Mental Illness. Archived from the original on October 3, 2013. Retrieved May 26, 2013.
  9. ^ "Jeffrey A. Lieberman Receives Hornick Award; Delivers Lecture on Early Interventions for Schizophrenia". The New York Academy of Medicine. January 12, 2012. Retrieved May 26, 2013.
  10. ^ "Previous Strecker Award Recipients". The Trustees of the University of Pennsylvania. Retrieved May 26, 2013.
  11. ^ Kendall, Joshua (2020-04-25). "Muzzled by Psychiatry in a Time of Crisis". Mad In America. Retrieved 2021-04-04.
  12. ^ Lee, Bandy X. (2021-01-07). "A Funny Thing Happened on Our Way to Alerting the Public …". Medium. Retrieved 2021-04-17.
  13. ^ "[COMMENTARY] Trumpism Did Not End With Donald Trump". HillReporter.com. 2021-02-22. Retrieved 2021-04-17.
  14. ^ "Shrinks: The Untold Story of Psychiatry by Jeffrey Lieberman – review". the Guardian. 2015-04-05. Retrieved 2021-04-04.
  15. ^ "Rainbow Light Home". Blessed Herbs. Archived from the original on 2016-12-21. Retrieved 2016-12-14.
  16. ^ "Jeffrey Lieberman, M.D." clintara.com. Archived from the original on 2016-06-24. Retrieved 2016-12-14.

External links[]

Retrieved from ""